Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 169

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 169
---
):Equity InvestmentsConvertible Notes ReceivableTotalBalance at December 31, 2023$15,877 $12,134 $28,011 Foreign currency adjustments— (236)(236)Balance at December 31, 202415,877 11,898 27,775 Purchases— 1,250 1,250 Impairment(4,000)(7,000)(11,000)Realized gain of prior investments (1)4,227 1,674 5,901 Settled investments (1)(8,315)(5,322)(13,637)Foreign currency adjustments(39)— (39)Balance at June 30, 2025$7,750 $2,500 $10,250 (1) In conjunction with the GQ Bio Acquisition, the settlement of the Company’s prior equity investment and notes receivable were part of the fair value of consideration exchanged. Upon acquiring the remaining 81% ownership interest in GQ Bio, the Company remeasured its previously held equity interest to its acquisition-date fair value. The $4.2 million gain resulting from the equity investment was recognized as other, net within the condensed consolidated statement of operations. In settling the notes receivable, the Company recognized $1.7 million in interest income. See Note 3, GQ Bio Therapeutics Acquisition, for information on the GQ Bio Acquisition.During the three and six months ended June 30, 2025, an impairment of an equity investment and convertible note receivable totaling $11.0 million was recorded in other, net in the condensed consolidated statements of operations.In June 2025, the Company invested $1.3 million in a convertible note receivable related to one of its existing early-stage strategic investments.Acquisition-Related Contingent ConsiderationThe Company has recognized contingent consideration related to the Flexion Acquisition in the amount of $17.2 million and $20.2 million as of June 30, 2025 and December 31, 2024, respectively. 

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 24

The Company’s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a Monte Carlo simulation. These